Brain cancer breakthrough? new trial delivers drug straight to tumor

NCT ID NCT05271240

Recruiting now Disease control Sponsor: Northwell Health Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase III trial is testing whether delivering the drug bevacizumab (Avastin) directly to the brain through a catheter, along with standard chemo and radiation, can help people with newly diagnosed glioblastoma live longer. The study will enroll 432 adults with this aggressive brain cancer. Earlier smaller studies suggested this approach might improve survival, but this larger trial will provide clearer answers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: bevacizumab (Avastin) delivered directly to the brain via a catheter
What this could lead to: If it works, this could offer a new, more effective way to treat glioblastoma, potentially extending survival beyond current standard care.
What could go wrong: This is an early phase III trial, so results are not guaranteed. The procedure carries risks from catheter use, and the drug may not improve outcomes for all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRAIN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adult glioblastoma brain cancer glioblastoma glioma glioma susceptibility 1 IDH-wildtype glioblastoma malignant glioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRAIN CANCER GBM GLIOBLASTOMA GLIOBLASTOMA MULTIFORME GLIOBLASTOMA MULTIFORME, ADULT GLIOBLASTOMA, IDH-WILDTYPE GLIOMA, MALIGNANT

Contacts and locations

Locations

Lenox Hill Brain Tumor Center
RECRUITING

New York, New York, 10075, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.